Expert Interview
Comparing Biogen's recently approved Spinraza to AveXis' pipeline drug AVXS-101 in treating spinal muscular atrophy
Ticker(s): BIIB, AVXSA neurologist familiar with treatment methods for spinal muscular atrophy. He or she will have experience diagnosing SMA, and will be familiar with relevant literature and data on both products.
Please describe your current practice. How many patients with Spinal Muscular Atrophy do you currently treat?
Since FDA approval, how has Spinraza manifested in the SMA market? What is the clinical consensus on the drug and how widely is it being prescribed?
What do you gather from the Phase 1 trials data for AVXS-101? Do you anticipate further success in the future trials?
How do the mechanisms for these two products differ, and which would you consider to be the more simple and minimally invasive?
In terms of patient convenience (cost, dosage requirements, etc), how do these drugs compare?
Added By: vanshb10Do either of these drugs have a significant side effect profile that would deter you from prescribing them to a patient?
On a scale of 1-10, 10 being very excited, how would you rate your level of excitement for each drug?
Added By: vanshb10Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
